Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer

Treating patients suffering from EGFR mutant non-small cell lung cancer (NSCLC) with first-generation EGFR tyrosine kinase inhibitors (EGFR TKI) provides excellent response rates. However, approximately 60% of all patients ultimately develop drug resistance due to a second T790M EGFR TKI mutation. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yanxia, Song, Zhendong, Jin, Yue, Tang, Zeyao, Kang, Jian, Ma, Xiaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274483/
https://www.ncbi.nlm.nih.gov/pubmed/27827863
http://dx.doi.org/10.3390/molecules21111462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274483/
https://www.ncbi.nlm.nih.gov/pubmed/27827863
http://dx.doi.org/10.3390/molecules21111462

Ejemplares similares